Prasugrel was the most effective drug to prevent post-PCI ischemic events but caused higher bleeding, whereas ticagrelor and high-dose clopidogrel provided the best balance of efficacy and safety.
Meta-Analysis
Do prasugrel, ticagrelor, and high-dose clopidogrel improve ischemic outcomes compared to standard-dose clopidogrel in patients undergoing PCI?
In patients undergoing PCI, prasugrel offers the greatest ischemic protection at the cost of increased bleeding, whereas ticagrelor and high-dose clopidogrel provide a more optimal balance of efficacy and safety.
Authors aimed to compare efficacy and safety of prasugrel, ticagrelor, and standard-dose (SD) and high-dose (HD) clopidogrel in patients undergoing percutaneous coronary intervention (PCI). PubMed, EMBASE, CENTRAL, and clinicaltrials.gov were searched for studies comparing prasugrel, ticagrelor, SD and HD clopidogrel in patients undergoing PCI. Frequentist and Bayesian network meta-analyses were performed besides direct pairwise comparisons. Thirty trials, comprising 34,563 person-year data, were included. Prasugrel emerged as a best drug to prevent definite or probable stent thrombosis, followed by HD clopidogrel and ticagrelor, with SD clopidogrel being the worst. Myocardial infarction was least likely to be prevented by SD clopidogrel after PCI, and remaining 3 were superior to it with little difference among them. SD clopidogrel was least effective in preventing cardiovascular deaths after PCI. Prasugrel was most effective in preventing cardiovascular deaths, although having only small advantage over ticagrelor and HD clopidogrel. Ticagrelor reduced all-cause mortality by a small margin compared with rest of treatments. SD clopidogrel, followed by ticagrelor, resulted in significantly lower thrombolysis in myocardial infarction major bleeding complications compared with prasugrel. Analysis of any bleeding revealed similar trend. HD clopidogrel performed better than prasugrel in terms of bleeding complications. In conclusion, Prasugrel is likely most effective drug to prevent post-PCI ischemic events but at the expense of higher bleeding. Ticagrelor followed by HD clopidogrel seems to strike the right balance between efficacy and safety. HD clopidogrel can be considered as an alternative to newer P2Y12 inhibitors.
Singh et al. (Thu,) conducted a meta-analysis in Percutaneous coronary intervention (PCI). Prasugrel, ticagrelor, and high-dose clopidogrel vs. Standard-dose clopidogrel was evaluated on Efficacy (stent thrombosis, myocardial infarction, cardiovascular deaths, all-cause mortality) and safety (major bleeding complications). Prasugrel was the most effective drug to prevent post-PCI ischemic events but caused higher bleeding, whereas ticagrelor and high-dose clopidogrel provided the best balance of efficacy and safety.